methylnaltrexone
Trade name: relistor
Small moleculeapproved
Approved
Apr 24, 2008
Methylnaltrexone, is a peripherally acting μ-opioid receptor antagonist that acts on the gastrointestinal tract to inhibit the opioid-induced decrease in gastric motility and transit time. It is used to treat opiate-induced constipation in adults with chronic non-cancer pain and in adults with advanced illness who are receiving palliative care. — NCATS
Clinical trial activity
68 trials · 28 clinical orgs · 6 marketing orgs
Phase 1
25
Phase 2
24
Phase 3
17
Phase 4
13
Earliest trial started Apr 1, 2002 (NCT01367574)
Timeline
2000s
- Jan 1, 2002
Bausch Health Companies — Earliest Phase 1 Sponsor(trial)
- Jan 1, 2002
Bausch Health Companies — Earliest Phase 2 Sponsor(trial)
- Jan 1, 2003
Bausch Health Companies — Earliest Phase 3 Sponsor(trial)
- Apr 24, 2008
Progenics — Earliest FDA Approval
- Apr 24, 2008
Salix — NDA Secondary Org
- Apr 24, 2008
Progenics — NDA Organization
2010s
- Jul 19, 2016
Bausch Health Companies — NDA Secondary Org
- May 3, 2017
Mylan — Marketing Organization
Indications
Approved for
Studied for
- Adult · Phase 1
- Coronary Artery Disease · Phase 4
- Enteral Nutrition · Phase 3
- Esophageal Diseases · Phase 4
- Gastroparesis · Phase 2
- General Surgery · Phase 3
- Healthy Volunteers · Phase 2
- Ileus · Phase 3
- Intestinal Diseases · Phase 2
- Intestinal Obstruction · Phase 1
- Kidney Failure, Chronic · Phase 1
- Liver Diseases · Phase 1
- Methadone · Phase 1
- Morphine · Phase 4
- Naltrexone · Phase 4
- Neoplasms · Phase 2
- Opioid-Induced Constipation · Phase 4
- Opioid-Related Disorders · Phase 2
- Pancreatic Neoplasms · Phase 3
- Pancreatitis · Phase 2/Phase 3
- Pharyngeal Diseases · Phase 4
- Postoperative Complications · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 4
- ST Elevation Myocardial Infarction · Phase 4
- Stomach Diseases · Phase 4
- Swallows · Phase 4
- Terminally Ill · Phase 3
- Ticagrelor · Phase 4
Mechanism of action
- Mu opioid receptorANTAGONIST
OPRM antagonist
Approval history
- approvedApr 24, 2008
Chemistry & pharmacology
Loading structure…
SMILES
C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5- Mol. weight
- 356.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1186579 ↗
- WikipediaMethylnaltrexone ↗
- NCATS0RK7M7IABE ↗
- ChEMBLCHEMBL1201770 ↗
Also known as
- 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinanium-6-one
- (5alpha)-17-(cyclopropylmethyl)-3,14-dihydroxy-17-methyl-4,5-epoxymorphinan-17-ium-6-one
- methylnaltrexone
- methylnaltrexone
- methylnaltrexone
- methylnaltrexone
- methylnaltrexone
- methylnaltrexone
- methylnaltrexone
- methylnaltrexone
- methylnaltrexone
- methylnaltrexone bromide
- methylnaltrexone bromide
- methylnaltrexone bromide
- methylnaltrexone bromide
- methylnaltrexone bromide
- methylnaltrexone bromide
- methyl-naltrexone hydrobromide
- methylnaltrexonium
- mntx
- mntx
- morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)-
- morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, bromide, (5alpha,17r)-
- morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, (5alpha)-
- mrz-2663
- mrz 2663br
- mrz-2663br
- mrz-2663br
- naltrexone mb
- naltrexone methobromide
- naltrexone methylbromide
- naltrexonium methiodide
- n-methylnaltrexone bromide
- n-methylnaltrexone bromide
- n-methylnaltrexone bromide
- quaternary ammonium naltrexone
- relistor
- relistor
- relistor
- relistor
- relistor
- relistor
- relistor
- relistor
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06162377 | Phase 4 | Apr 30, 2024 | University of Texas at Houston |
| NCT04787848 | N/A | Nov 15, 2021 | University of Alabama, Birmingham |
| NCT04743570 | Phase 2/Phase 3 (Phase 3) | May 10, 2021 | Aalborg University, University of Copenhagen, University of Southern Denmark |
| NCT04151719 | Phase 3 | Feb 3, 2020 | Bausch Health Companies |
| NCT04083651 | Phase 2/Phase 3 (Phase 3) | Oct 15, 2019 | Bausch Health Companies |
| NCT03852524 | Phase 2 | Jan 25, 2019 | Ohio State University |
| NCT03523520 | Phase 4 | Jul 1, 2018 | University of Missouri |
| NCT03283020 | Phase 4 | Nov 11, 2017 | Orebro University |
| NCT02942550 | Phase 4 | Nov 1, 2016 | Karolinska Institute |
| NCT02977286 | Phase 4 | Nov 1, 2016 | Tufts University |
| NCT02403830 | Phase 4 | Aug 1, 2015 | University of Florida |
| NCT02574819 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2015 | Huazhong University of Science and Technology, Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT01889290 | Phase 1 | Feb 1, 2014 | University of Zurich |
| NCT03014843 | N/A | Oct 1, 2013 | Katholieke Universiteit Leuven |
| NCT01773096 | Phase 4 | May 1, 2013 | Shriners Hospitals for Children |
| NCT01596764 | Phase 1 | May 1, 2011 | University of Greifswald |
| NCT01360372 | Phase 3 | Oct 1, 2010 | Drexel University, Wyeth |
| NCT01186770 | Phase 3 | Sep 1, 2010 | Bausch Health Companies, Progenics |
| NCT01366326 | Phase 1 | Jul 1, 2010 | Bausch Health Companies, Progenics |
| NCT01117376 | Phase 2 | May 1, 2010 | University of Tehran |
Showing 20 of 68 trials
Page 1 / 4
Organizations
Research & Development (28)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bausch Health Companies | For profit | 46 | 46 | 5 | 2002 |
| Progenics | For profit | 31 | 0 | 5 | 2002 |
| Wyeth | For profit | 8 | 0 | 3 | 2004 |
| Orebro University | Academic/Hospital | 2 | 2 | 1 | 2009 |
| Pfizer | For profit | 2 | 0 | 1 | 2003 |
| University of Greifswald | Academic/Hospital | 2 | 2 | 1 | 2010 |
| Aalborg University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Drexel University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 1 | 1 | 1 | 2015 |
| Karolinska Institute | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Shriners Hospitals for Children | Academic/Hospital | 1 | 1 | 1 | 2013 |
| St. John Health System, Michigan | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Tufts University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2021 |
28 organizations
Page 1 / 2
Marketing (8)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Actavis | For profit | MKTG | Aug 26, 2024 |
| Bausch Health Companies | For profit | NDA2 | Jul 19, 2016 |
| Mylan | For profit | MKTG | May 3, 2017 |
| Progenics | For profit | NDA | Apr 24, 2008 |
| Salix | For profit | NDA2 | Apr 24, 2008 |
| Salix | For profit | SYN | Jul 19, 2016 |
| Salix | For profit | SYN | Jul 19, 2016 |
| Teva | For profit | MKTG | Aug 12, 2021 |